Cleveland Virginia, Ohio Participate in Clinical Trials to Test Experimental COVID-19 Vaccine in Humans

Cleveland, Ohio — Two Ohio Research Centers — Louis Stokes Cleveland Virginia Medical Center And that Ohio State University Wexner Medical Center—I’m looking for a safe and effective COVID-19 vaccine.

Cleveland VA is one of more than 120 clinical trial sites worldwide that collectively enrolls up to 30,000 participants in a statement-published vaccine trial. This study collects data on the safety and immune response of the proposed vaccine BNT162b2.

Proposed COVID-19 vaccine developed by Pfizer and a German biotechnology company BioNTech SE.

Cleveland VA Trial

Cleveland VA is the only VA hospital hosting clinical trials for Pfizer vaccine, writes US Veterans Secretary Robert Wilkie In a recent opinion.

“The Cleveland VA Medical Center was selected as the only VA to participate in this study because of its track record of incorporating veterans in vaccine trials, supported by a strong clinical research program.” Dr. Curtis Donsky, Head of infection control in Cleveland Virginia. “We feel it is important to get veterans involved in this important effort. VA has identified chronic illnesses at high risk for serious outcomes due to COVID-19. Provides care to many veterans with.”

Cleveland Virginia’s Clinical Research Center Directors Donsky and Maraguette Ticktin lead the research here.

The VA Phase 2/3 study aims to enroll healthy non-pregnant adults aged 18 to 85 at risk for COVID-19 infection. Veterans are prioritized regardless of whether they are enrolled in VA Care.

According to the VA, an equal number of participants will receive the vaccine and placebo during the VA trial.

The clinical development of new drugs and vaccines is a three-phase process Center for Disease Control and Prevention. In Phase 1, a small number of people get the clinical trial vaccine. In Phase 2, the trial vaccine will be given to people who have similar characteristics to those who are the target of the new vaccine. In Phase 3, the vaccine will be given to thousands of people to be tested for efficacy and safety.

Those interested in participating in research through the Cleveland VA Medical Center can call the 216-791-3800 extension. 65273. Once the maximum number of participants has been reached, VA will track interested participants for potential future research, the VA Center said.

Wexner Medical Center Exam

The Wexner Medical Center will be a multicenter 30,000-person clinical trial site testing COVID-19 vaccines, Ohio recently announced.

The vaccine is called AZD1222 and was co-developed by Oxford University and a biopharmaceutical company. AstraZeneca, Ohio said in a statement.

In large-scale early clinical trials in the UK, the vaccine produces a safe and strong immune response that produces both antibodies and T cells that detect and attack viral cells, the university says.

“Time is important to develop vaccines and/or drugs that can stop the transmission of (coronavirus) and reduce the serious health effects and deaths caused by COVID-19.” Dr Susan ColetteHe was in charge of the Infectious Diseases Department at Ohio State Wexner Medical Center and is the principal investigator in the vaccine trial, he said in a statement.

A randomized, double-blind, placebo-controlled trial to evaluate how the AZD1222 vaccine protects people from COVID-19 requires approximately 500 adults.

The Wexner Medical Center study is looking for participants at high risk of exposure to COVID-19.

Study participants will receive either an vaccine or placebo, take a blood sample, and be followed up by a healthcare professional for two years. For those interested in applying for the AZD1222 clinical trial, Please click here.

Results of other clinical trials conducted through the Wexner Medical Center and the COVID-19 Prevention Network said they are important for bringing the COVID-19 vaccine to market Dr. Ramamaran Paris, Internal medicine chair Ohio State University School of Medicine, In the statement.

The National Institute of Allergy and Infectious Diseases has used its infectious disease expertise in four existing clinical trial networks to create the COVID-19 Prevention Network. This has allowed the network to quickly set up COVID-19 clinical trials at sites with a long history of research and collaboration, Malampari said.

University hospital

UH joins The hospital system has recently introduced about 120 clinical trial sites worldwide, enrolling up to 30,000 participants in a trial to test the proposed COVID-19 vaccine. Phase 2/3 vaccine research sponsored Pfizer Japan Inc And BioNTech SE.

The new trial enrolls non-pregnant adults aged 18 to 85. Due to the disproportionate proportion of COVID-19 among people of color, according to the hospital system, UH plans to ensure that people of color are well represented in this study. Please call 612-524-9091 for how to participate.